Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Sponsor: Haya Therapeutics, Inc.
Summary
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HTX-001 in human adult participants.
Official title: A Two-Part, Phase 1, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and WISPER Target Engagement of HTX-001 in Adult Healthy Participants (Part 1) and in Adult Participants With Nonobstructive Hypertrophic Cardiomyopathy (Part 2)
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2026-10
Completion Date
2027-03
Last Updated
2026-10-09
Healthy Volunteers
Yes
Interventions
HTX-001
HTX-001 is an investigational antisense oligonucleotide (ASO)
Locations (1)
Saint Luke's Health System
Kansas City, Missouri, United States